The antiandrogen bicalutamide is commonly used in combination with medical or surgical castration in men with prostate cancer. With combined androgen blockade, the usual dose of bicalutamide is 50 mg per day, but evidence suggests that higher doses might be beneficial.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Klotz, L. et al. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study. Prostate Cancer Prostatic Dis. 17, 320–324 (2014).
Bales, G. T. & Chodak, G. W. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 47, 38–43 (1996).
Labrie, F., Simard, J., Singh, S. M. & Candas, B. Estimated potency of Casodex: a problematic design. Urology 50, 309–313 (1997).
Labrie, F. et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin. Invest. Med. 5, 267–275 (1982).
Prostate Cancer Triallists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355, 1491–1498 (2000).
Labrie, F. et al. Benefits of combination therapy with flutamide in patients relapsing after castration. Br. J. Urol. 61, 341–346 (1988).
Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).
Blackledge, G. R. Clinical progress with a new antiandrogen CasodexTM (Bicalutamide). Eur. Urol. 29, 96–104 (1996).
Schellhammer, P. et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 45, 745–752 (1995).
Akaza, H. et al. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J. Urol. 176, S47–S49 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Labrie, F. Bicalutamide dose increase in castration-resistant disease. Nat Rev Urol 12, 132–133 (2015). https://doi.org/10.1038/nrurol.2014.334
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.334
This article is cited by
-
Preclinical models of prostate cancer — modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo
Nature Reviews Urology (2023)
-
Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer
International Urology and Nephrology (2015)
